Business
Telo Genomics Launches Retrospective Blood-Based MRD Study with University of Athens as Part of 2026 Multi-Center Validation Program
Toronto, Ontario--(Newsfile Corp. - December 18, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB:...
About this update from Telo Genomics Corp.
[{"type":"text","content":"Telo Genomics Launches Retrospective Blood-Based MRD Study with University of Athens as Part of 2026 Multi-Center Validation ProgramToronto, Ontario--(Newsfile Corp. - December 18, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the \"Company\" or \"Telo\"), a leader in diagnostic and prognostic innovation through advanced telomere analytics, today announced the initiation of a new multiple myeloma (MM) Minimal Residual Disease (MRD) clinical trial in collaboration with the University of Athens. This retrospective study is a key component of Telo's expanding, multi-center MRD validation program and is designed to evaluate the clinical utility of Telo's blood-based TeloView®MRD. The University of Athens collaboration provides access to well-characterized clinical blood samples with retrospectively available patient outcomes and an average of approximately three years of follow-up, along with existing serial Next-Generation Flow (\"NGF\") MRD results. The study is intended to assess the prognostic performance of TeloView®MRD in predicting patients' risk of relapse and to compare that performance to NGF, one of the two most widely used MRD assessment approaches in MM (alongside Next-Generation Sequencing, \"NGS\"). The cohort includes NGF MRD results available in both blood and bone marrow, supporting a robust comparative dataset.TeloView®MRD is designed to detect disease at high sensitivity in blood, with an expected limit of detection down to 1 in 10^7 (one myeloma cell among 10 million blood cells) across different disease stages. In comparison, NGF can reach 10^6 sensitivity in some centers. In addition to MRD enumeration, TeloView®MRD analyzes the 3D genomic architecture of individual MRD cells, which may provide incremental prognostic insight beyond cell counting alone.Telo continues to advance its prospective MRD trials with Cleveland Clinic and Jewish General Hospital. The Company also expects to announce additional retrospective collaborative studies in Q1 2026 as it builds a multi-center, large-scale clinical evidence package to support adoption and demonstrate comparative performance versus established MRD assays.\"We are pleased to be working with Prof. Meletios A. Dimopoulos and Prof. Efstathios Kastritis from the National and Kapodistrian University of Athens,\" said Dr. Sabine Mai, Telo's...